Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Emerg Med Australas ; 35(1): 25-33, 2023 02.
Artigo em Inglês | MEDLINE | ID: mdl-35859101

RESUMO

OBJECTIVE: The aim of the present study was to obtain an unbiased understanding of the prevalence of psychoactive drugs in trauma patients presenting to a large ED. METHODS: Consecutive adult patients presenting to the ED with an injury resulting in a trauma call had an anonymised, additional blood test taken for detection of over 2000 drugs. Laboratory testing was to judicial standards. Drugs given by ambulance pre-hospital were detected but excluded from the analysis. RESULTS: Over 6 months 276 (74.7%) of 371 patients were tested. Of the 276 patients tested, 158 (57.2%) had one or more psychoactive drug present. Recreational drugs were detected in 101 (36.6%) patients and medicinal drugs in 88 (31.8%) patients, with a combination of both detected in 31 (11.2%) patients. The most common drugs detected were cannabis (22.1%), antidepressants (18.4%), alcohol (15.5%), opioids (10.1%), benzodiazepine/z-drugs (9.4%) and methamphetamine (7.2%). The prevalence of psychoactive drugs differed by age group, sex and cause of injury. CONCLUSIONS: The prevalence of psychoactive drugs in injury presentations to an ED is high, and provides an opportunity to reduce harm. The present study demonstrates the feasibility of an approach which limits bias and obtains results that accurately reflect the drug prevalence in injured cohorts. Systematic testing of injured patients is an important contribution to the epidemiology of injury.


Assuntos
Drogas Ilícitas , Transtornos Relacionados ao Uso de Substâncias , Adulto , Humanos , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Prevalência , Drogas Ilícitas/efeitos adversos , Psicotrópicos/efeitos adversos , Serviço Hospitalar de Emergência
2.
EClinicalMedicine ; 25: 100460, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32743487

RESUMO

BACKGROUND: AMB-FUBINACA is a synthetic cannabinoid that has been associated with periodic outbreaks of acute poisonings, but few fatalities. In late May, June and July 2017 Auckland, New Zealand, experienced an outbreak of deaths associated with AMB-FUBINACA that continued at a rate of about 2-3 per month through February 2019. The aim of this study was to define the demographic, circumstantial, pathological and toxicological characteristics of this outbreak. METHODS: All records of the Northern Forensic Pathology Service, Auckland Hospital, were reviewed in which the word "AMB-FUBINACA" was referenced, including initial police reports, autopsy reports and toxicology reports. Recorded data included age, sex, race/ethnicity, times and locations, cause of death, autopsy and toxicology findings, and a brief summary of the circumstances of death. Descriptive statistics were performed using IBM® SPSS® Statistics Version 24 and Microsoft® Excel® Version 14.7.2. FINDINGS: Sixty-four cases were identified. One sudden infant death and five cases where cause of death was due to trauma were excluded. Of the remaining 58 cases, 88% were male. Mean age was 42 years. In 95% of the deaths, AMB-FUBINACA alone or in combination with alcohol or another drug was listed as the primary or contributory cause of death. In 41 cases postmortem blood concentrations of AMB-FUBINACA acid were available, ranging from <45 ng/mL to >1000 ng/mL, mean 229 ng/mL, median 140 ng/mL. Comorbidities identified included mixed intoxications (29%), heart disease (47%) and obesity (16%). A mental health diagnosis was reported in 50%, and 40% were on antipsychotic medications. INTERPRETATION: This study presents characteristics, comorbidities and toxicological findings in a unique outbreak of deaths associated with the synthetic cannabinoid AMB-FUBINACA in Auckland, NZ. FUNDING: All work was funded as part of the usual employment of the authors in their respective institutions. No special funding sources are reported.

3.
Drug Test Anal ; 12(2): 195-214, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31595682

RESUMO

We describe the validation of a method for the simultaneous analysis of 29 synthetic cannabinoids (SCs) and metabolites, 4 amphetamines, and 2 cannabinoids in human whole blood. This method enables one analysis to cover what previously required multiple analyses for these classic and novel drugs-of-abuse with diverse physicochemical properties. The scope of targeted analytes was based on the most prevalent drugs-of-abuse and SCs encountered at the New Zealand border in 2017 and included parent compounds and metabolites belonging to the indole and indazole carboxamide, quinolinyl indole carboxylate, and naphthoylindole classifications. Samples were prepared by supported-liquid-extraction (SLE) followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis with positive electrospray ionization (ESI). The method was validated with respect to selectivity, matrix effects, process efficiency, sensitivity, repeatability, extract stability, and carryover for qualitative confirmation. Linearity as well as accuracy and precision data at target decision concentrations were also evaluated. The limits of detection and confirmation ranged from 0.1 to 6.0 ng/mL and 1.0 to 6.0 ng/mL, respectively. The described method was successfully applied to the analysis of 564 ante- and post-mortem blood samples in 2018. There were 132 cases (23%) with positive findings of at least one SC, with the five most commonly detected SCs being AMB-FUBINACA and/or acid (61%), 5F-ADB and/or acid (40%), ADB-FUBINACA (11%), 5F-MDMB-PICA acid (6%), and MDMB-FUBINACA acid (6%). The results also demonstrate the predominant presence of metabolites at higher levels than the unchanged parent SCs in blood, highlighting the need to maintain forensic screening methods capable of the simultaneous detection of both parent compounds and metabolites.


Assuntos
Anfetaminas/sangue , Canabinoides/sangue , Drogas Ilícitas/sangue , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/métodos , Anfetaminas/metabolismo , Canabinoides/metabolismo , Cromatografia Líquida/métodos , Humanos , Drogas Ilícitas/metabolismo , Limite de Detecção , Extração Líquido-Líquido/métodos , Nova Zelândia
4.
N Z Med J ; 125(1362): 15-25, 2012 Sep 21.
Artigo em Inglês | MEDLINE | ID: mdl-23178601

RESUMO

AIM: Determine major substances and risk factors for suicide by chemical overdose in New Zealand between 2001 and 2005. METHOD: All intentional deaths between 2001 and 2005 were reviewed. Primary substances causing death were verified from toxicology reports. RESULTS: The chemical suicide rate was higher among older Europeans, women and those in paid work than other groups. Carbon monoxide and tricyclic antidepressants (TCAs) continue to be the most common chemicals used, in spite of market changes. Anaesthetics and cyanide deaths among workers were noted. CONCLUSION: Restricted access to work-related chemicals and stricter prescription/dispensing controls for TCAs may reduce self-poisoning in New Zealand.


Assuntos
Overdose de Drogas/mortalidade , Intoxicação/mortalidade , Suicídio/estatística & dados numéricos , Adolescente , Adulto , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Antidepressivos/intoxicação , Antidepressivos Tricíclicos/intoxicação , Povo Asiático/estatística & dados numéricos , Intoxicação por Monóxido de Carbono/mortalidade , Causas de Morte , Feminino , Humanos , Hipnóticos e Sedativos/intoxicação , Masculino , Pessoa de Meia-Idade , Entorpecentes/intoxicação , Havaiano Nativo ou Outro Ilhéu do Pacífico/estatística & dados numéricos , Nova Zelândia/epidemiologia , Estudos Retrospectivos , Distribuição por Sexo , Fatores Socioeconômicos , Toxicologia/estatística & dados numéricos , Desemprego/estatística & dados numéricos , População Branca/estatística & dados numéricos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA